1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Beta Bionics priced an underwritten public offering of 7,652,175 common shares at $17.25 per share, plus pre-funded warrants for 1,043,484 shares, with gross proceeds expected to be about $150.0 million before underwriting discounts and expenses. The company expects to use the net proceeds for general corporate purposes, including costs of commercializing Mint and manufacturing expansion, and the offering is expected to close on September 17, 2026. The sale of new shares will increase the number of shares outstanding, which affects existing shareholders' ownership.
Offering of 7,652,175 common shares at $17.25 per share, plus pre-funded warrants for 1,043,484 shares at $17.2499 per share
Gross proceeds expected to be about $150.0 million before underwriting discounts and offering expenses
Underwriters have a 30-day option to buy up to 1,304,348 additional shares at the public offering price
Expected closing on September 17, 2026; J.P. Morgan, Piper Sandler, Wells Fargo Securities and Leerink Partners are the underwriters
American Battery Technology reported fiscal 2026 results for the year ended June 30, 2026, with revenue up 407% to $21.7 million and a net loss of $73.4 million, compared with $46.8 million a year earlier. Loss per share was $0.58 in both years, and cash rose to $49.5 million with no outstanding debt, though the filing gives no forward guidance.
Revenue rose to $21.7 million from $4.3 million in fiscal 2025.
Net loss attributable to common stockholders was $73.4 million, versus $46.8 million; basic and diluted loss per share was $0.58 in both years.
Adjusted gross profit (non-GAAP) was $1.7 million, compared with an adjusted gross loss of $6.2 million in fiscal 2025.
Cash and cash equivalents were $49.5 million as of June 30, 2026, up from $7.5 million, and the company reported no outstanding debt.
On September 11, 2026, ProFrac and the parties to its Alpine term loan signed Amendment No. 5, which cuts required quarterly principal payments to $0 through March 31, 2028 and extends maturity to February 15, 2030. The same day, $60 million of term loans was assigned to THRC Holdings and Farris C. Wilks, a co-founder and principal stockholder, and was repaid through the transfer of 2,306,806 Flotek shares owned by a ProFrac subsidiary, which gives the company near-term repayment relief but also a related-party transaction and tighter cash-flow and distribution terms.
Quarterly amortization reduced from $15 million to $0 for quarters ending September 30, 2026 through March 31, 2028, then $10 million per quarter.
Maturity extended from January 26, 2029 to February 15, 2030; PFP Holding may pay 675 basis points of interest in kind for 12 months from September 1, 2026.
$60 million of 2026 Term Loans assigned to THRC Holdings ($34.32 million) and Farris C. Wilks ($25.68 million) and cancelled in exchange for 2,306,806 Flotek shares.
Borrower must prepay 100% of excess cash flow each quarter, and company distributions are restricted to a $1 million annual basket.
On September 15, 2026, My Size agreed to sell up to 1,308,901 shares of common stock, or pre-funded warrants in their place, at $1.91 each, along with Series C and Series D warrants, in a private placement expected to bring in about $2.5 million in gross proceeds before fees. The warrants are exercisable at $1.66 per share, so the deal would add up to roughly 2.6 million potential shares to the share count, which dilutes existing shareholders, and the company says the proceeds will go to general corporate purposes, including working capital.
Up to 1,308,901 shares or pre-funded warrants at $1.91 each; gross proceeds of about $2.5 million before placement agent fees and expenses
Series C and Series D warrants, each for up to 1,308,901 shares, exercisable immediately at $1.66 per share; Series C term is five years and Series D term is 18 months from the resale registration effective date
H.C. Wainwright & Co. is exclusive placement agent, with a 7% cash placement fee, a 1.0% management fee and placement agent warrants for 91,623 shares at $2.3875
Offering expected to close on or about September 16, 2026; company must file a resale registration statement within 15 days of signing and is barred from variable rate transactions for one year after the effective date
ACP Holdings Acquisition Corp., a Cayman Islands special purpose acquisition company, signed a business combination agreement on September 15, 2026, under which May Mobility, Inc. would merge into a subsidiary of ACP and become a publicly listed company named May Mobility, Inc. on Nasdaq under the ticker MAY. ACP shareholders must approve the deal, and the 8-K sets an outside closing date of May 26, 2027, while the press release says closing is expected by year-end; the amount of gross proceeds depends on how many public shareholders redeem their shares.
Aggregate consideration to May Mobility holders is based on a $1.35 billion purchase price at $10.00 per share, with a pro forma enterprise value of approximately $1.4 billion.
Gross proceeds of up to $337 million, including up to $217 million from the ACP trust account (subject to redemptions) and a fully committed $120 million PIPE.
Closing is expected on or before May 26, 2027, subject to ACP and May Mobility shareholder approvals and other customary conditions.
May Mobility generated approximately $10 million in revenue and burned approximately $93 million in cash in 2025, according to the press release.
Xenetic Biosciences agreed on September 14, 2026 to acquire all share capital of Swiss company Santersus AG in exchange for newly issued Xenetic common stock, subject to Xenetic stockholder approval and other conditions. On a pro forma basis, existing Xenetic equity holders would own about 15.0% of the combined company and Santersus equity holders about 85.0%, subject to adjustment based on Xenetic's net cash at closing, so current shareholders' stake would be substantially diluted.
Santersus equity holders expected to own about 85.0% and Xenetic equity holders about 15.0% of the combined company on a fully diluted basis.
Closing is expected in the fourth quarter of 2026, subject to stockholder approval, Nasdaq listing approval and an effective Form S-1 resale registration statement.
Xenetic may owe Santersus a $500,000 termination fee under specified circumstances; either party may reimburse the other for fees and expenses up to $300,000.
The combined company would be renamed Santersus Bio, Inc. with an eight-member board, six designated by Santersus, and expected to trade under the symbol SNTS.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.